beyond efficacy hard outcomes in treatment studies
play

Beyond Efficacy: Hard Outcomes in Treatment Studies Guy Goodwin, - PowerPoint PPT Presentation

Feb 25, 2024 •113 likes •157 views

Beyond Efficacy: Hard Outcomes in Treatment Studies Guy Goodwin, University of Oxford, UK ISCTM ~ ECNP Joint Conference 1 September 2017 Paris France Is there a problem? Efficacy and safety Effectiveness, safety (and established

  1. Beyond Efficacy: Hard Outcomes in Treatment Studies Guy Goodwin, University of Oxford, UK ISCTM ~ ECNP Joint Conference ▪ 1 September 2017 ▪ Paris ▪ France

  2. Is there a problem? Efficacy and safety Effectiveness, safety (and established reimbursemen) Well validated scales Hard outcomes Randomized clinical trial (economic data) Placebo Non-random Short & long term data No placebo Key is long term

  3. Randomized clinical trials Pro Contra Narrow inclusion and exclusion Highest level of evidence criteria limits generalisability Low risk for systematic bias Difficult to demonstrate effect Demonstrate “ efficacy ” of old drugs “Enriched design” benefits the study drug Do not show “ effectiveness ” in the real world Expensive Long-term trials might be unethical

  4. The agenda for this session

Recommend

RIGHT PATIENT, RIGHT TREATMENT, RIGHT TIME: Utilizing Early, High-Efficacy Therapies to Improve

RIGHT PATIENT, RIGHT TREATMENT, RIGHT TIME: Utilizing Early, High-Efficacy Therapies to Improve

RIGHT PATIENT, RIGHT TREATMENT, RIGHT TIME: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS Supported by educational grants from Celgene Corporation, a Bristol Myers Squibb company Provided by and from Genentech, a

505 views • 46 slides
Assessment of efficacy of Level 1 MPB treatment using neighborhood analysis Outline 1. Annual

Assessment of efficacy of Level 1 MPB treatment using neighborhood analysis Outline 1. Annual

Assessment of efficacy of Level 1 MPB treatment using neighborhood analysis Outline 1. Annual Aerial Surveys with Treatment Points 2. Brief Review of Level 1 Treatment 3. Overview of Neighborhood Analysis Method 4. Results and Discussion F

487 views • 22 slides
Phase III studies of direct oral anticoagulants for treatment and prevention of VTE Dabigatran,

Phase III studies of direct oral anticoagulants for treatment and prevention of VTE Dabigatran,

Phase III studies of direct oral anticoagulants for treatment and prevention of VTE Dabigatran, apixaban, edoxaban and rivaroxaban Phase III VTE acute treatment studies Trial name Design Initial treatment Treatment Long-term Active with

709 views • 19 slides
Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2):

Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2):

Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo- controlled, randomised trial Massimo Imazio, MD, FESC on behalf of the CORP-2 Investigators Cardiology

470 views • 20 slides
Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram- Positive Infections

Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram- Positive Infections

Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram- Positive Infections Vanessa Brown, Pharm.D. Collaborators: PGY-1 Pharmacy Practice Resident Ryan Moenster, Pharm.D., FIDSA, BCPS-AQ ID St. Louis VA Health Care

512 views • 23 slides
CAR T-Cell Therapy: Efficacy, Treatment, Access Michael I. Nishimura, Ph.D. Professor of Surgery

CAR T-Cell Therapy: Efficacy, Treatment, Access Michael I. Nishimura, Ph.D. Professor of Surgery

CAR T-Cell Therapy: Efficacy, Treatment, Access Michael I. Nishimura, Ph.D. Professor of Surgery and Vice Chair for Surgery Research Stritch School of Medicine Tumor Immunology & Immunotherapy Program Cardinal Bernardin Cancer Center

791 views • 48 slides
Issues Translation Efficacy/adverse reactions Risk/resilience/outcomes Modification

Issues Translation Efficacy/adverse reactions Risk/resilience/outcomes Modification

Issues Translation Efficacy/adverse reactions Risk/resilience/outcomes Modification of Mendelian disorder Oligogenic diseases Complex diseases Study design (next session) & Bandwidth of project

242 views • 3 slides
Brownian dynamics simulations with hard-body interactions: Exact numerical treatment PHYSICAL

Brownian dynamics simulations with hard-body interactions: Exact numerical treatment PHYSICAL

Brownian dynamics simulations with hard-body interactions: Exact numerical treatment PHYSICAL REVIEW E 83 , 065701(R) (2011) Ralf Eichhorn Hard-wall interactions in soft matter systems: Exact numerical treatment Hans Behringer 1,* and Ralf

490 views • 21 slides
Infectious complications in MS: An audit of high efficacy therapies pre-treatment screening and

Infectious complications in MS: An audit of high efficacy therapies pre-treatment screening and

Infectious complications in MS: An audit of high efficacy therapies pre-treatment screening and risk mitigation Olivia Moswela Pharmacist OUH Background No gold standard for infection screening / risk mitigation prior to initiating DMTs

256 views • 12 slides
Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Efficacy, Safety, and Tolerability of

Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Efficacy, Safety, and Tolerability of

Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine:

336 views • 15 slides
Communication Access Tips for Deaf and Hard of Hearing Individuals While Getting Treatment for

Communication Access Tips for Deaf and Hard of Hearing Individuals While Getting Treatment for

NJ DIVISION FOR THE DEAF AND HARD OF HEARING Communication Access Tips for Deaf and Hard of Hearing Individuals While Getting Treatment for COVID-19 State of New Jersey Phil Murphy, Governor Sheila Oliver, Lt. Governor NJ Departmet of Human

90 views • 5 slides
Measuring outcomes in the advice sector Hazel Genn Why do we need to measure outcomes? Service

Measuring outcomes in the advice sector Hazel Genn Why do we need to measure outcomes? Service

Measuring outcomes in the advice sector Hazel Genn Why do we need to measure outcomes? Service quality Efficacy Efficiency Allocate resources Fund raising What is the problem? Law and legal services are not evidence based Adapted from

698 views • 12 slides
Coordinating ng M Medical al T Treatment f for Des esired O Outcomes i in W Wor

Coordinating ng M Medical al T Treatment f for Des esired O Outcomes i in W Wor

Coordinating ng M Medical al T Treatment f for Des esired O Outcomes i in W Wor orkers Compensatio ion: A : A Panel D Discu cussion Presenters: Edward J. Bernacki, MD, MPH - Professor of Population Health, Executive Director of

481 views • 20 slides
RELATIVE LETHAL DOSE, A TIME-TEMPERATURE MODEL FOR RELATING SOIL SOLARIZATION EFFICACY AND

RELATIVE LETHAL DOSE, A TIME-TEMPERATURE MODEL FOR RELATING SOIL SOLARIZATION EFFICACY AND

RELATIVE LETHAL DOSE, A TIME-TEMPERATURE MODEL FOR RELATING SOIL SOLARIZATION EFFICACY AND TREATMENT DURATION FOR NEMATODE CONTROL J.W. Noling Much of the previous soil solarization research has involved efficacy assessments of soilborne pest

492 views • 5 slides
Drug Efficacy and Response Minutes of the TEG on Drug Efficacy and Response Malaria Policy

Drug Efficacy and Response Minutes of the TEG on Drug Efficacy and Response Malaria Policy

Drug Efficacy and Response Minutes of the TEG on Drug Efficacy and Response Malaria Policy Advisory Committee, Geneva, Switzerland, 16 March 2016 Outline Update on artemisinin resistance Monitoring efficacy and effectiveness of

765 views • 30 slides
IG Therapy How to Individualize Your Treatment plan to have best outcomes with least side

IG Therapy How to Individualize Your Treatment plan to have best outcomes with least side

IG Therapy How to Individualize Your Treatment plan to have best outcomes with least side effects, and How to ensure your insurance plan will cover IVIG/SCIG James L. Sheets, PharmD, CEO Michelle B. Vogel, MPA, VP Patient Advocacy &

809 views • 35 slides
CASTLE: 48- -Week Results Week Results CASTLE: 48 J. M. Molina, 1 J. Andrade-Villanueva, 2 J.

CASTLE: 48- -Week Results Week Results CASTLE: 48 J. M. Molina, 1 J. Andrade-Villanueva, 2 J.

Efficacy and Safety of Boosted Once- -Daily Daily Efficacy and Safety of Boosted Once Atazanavir and Twice- -Daily Lopinavir Daily Lopinavir Atazanavir and Twice Regimens in Treatment- -Na Na ve ve Regimens in Treatment HIV- -1

185 views • 14 slides
Erit Eritrea Field St rea Field Studies udies on Efficac on Efficacy of of Bacteri Bacterial

Erit Eritrea Field St rea Field Studies udies on Efficac on Efficacy of of Bacteri Bacterial

Activity Report 112 Erit Eritrea Field St rea Field Studies udies on Efficac on Efficacy of of Bacteri Bacterial Larvicides al Larvicides for Use in Malaria Control for Use in Malaria Control by Josephat Shililu December 2001 Prepared

300 views • 27 slides
Looking for a simple method to combine hard + 0 jet and hard + 1 jet event generators

Looking for a simple method to combine hard + 0 jet and hard + 1 jet event generators

Looking for a simple method to combine hard + 0 jet and hard + 1 jet event generators Shigeru ODAKA Institute of Particle and Nuclear Studies High Energy Accelerator Research Organization (KEK) shigeru.odaka@kek.jp Motivation

346 views • 19 slides
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in

Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in

Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics and Epidemiology Research Office

233 views • 10 slides
A decade of 3Rs research at the MEB: Realising an optimal safety and efficacy assessment with a

A decade of 3Rs research at the MEB: Realising an optimal safety and efficacy assessment with a

A decade of 3Rs research at the MEB: Realising an optimal safety and efficacy assessment with a minimum of animal studies dr. Peter van Meer 13-02-2020 Conflict of interest statement(s) The statements and opinions in this presentation are not

559 views • 18 slides
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine, for the FOURIER Steering Committee &

214 views • 19 slides
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine, for the FOURIER Steering Committee &

353 views • 8 slides
Efficacy and Crop Safety Data Development Issues David Richardson Pesticides Safety Directorate

Efficacy and Crop Safety Data Development Issues David Richardson Pesticides Safety Directorate

Global Minor Uses Summit Efficacy and Crop Safety Data Development Issues David Richardson Pesticides Safety Directorate York, UK. Content Content Efficacy why efficacy? Efficacy why efficacy? Working to common

349 views • 24 slides

More recommend